Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Director Molly Harper Sells 17,500 Shares

Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Director Molly Harper sold 17,500 shares of the company’s stock in a transaction dated Wednesday, November 27th. The stock was sold at an average price of $22.00, for a total transaction of $385,000.00. The sale was disclosed in a document filed with the SEC, which is accessible through this link.

Catalyst Pharmaceuticals Stock Down 1.2 %

Shares of NASDAQ:CPRX traded down $0.27 during trading on Friday, hitting $22.07. 554,323 shares of the company traded hands, compared to its average volume of 1,187,151. The stock has a market capitalization of $2.63 billion, a price-to-earnings ratio of 18.70, a PEG ratio of 3.44 and a beta of 0.75. Catalyst Pharmaceuticals, Inc. has a one year low of $13.00 and a one year high of $24.27. The business’s fifty day moving average is $21.23 and its 200-day moving average is $18.72.

Wall Street Analysts Forecast Growth

A number of research analysts have recently weighed in on CPRX shares. StockNews.com raised shares of Catalyst Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Friday, August 9th. Stephens began coverage on shares of Catalyst Pharmaceuticals in a research note on Monday, November 18th. They set an “overweight” rating and a $35.00 price objective for the company. HC Wainwright restated a “buy” rating and set a $30.00 target price on shares of Catalyst Pharmaceuticals in a report on Friday, November 8th. Citigroup upped their price target on Catalyst Pharmaceuticals from $27.00 to $31.00 and gave the stock a “buy” rating in a report on Friday, August 9th. Finally, Truist Financial boosted their target price on shares of Catalyst Pharmaceuticals from $30.00 to $36.00 and gave the stock a “buy” rating in a research report on Monday, November 11th. Seven investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Buy” and an average price target of $31.14.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in the stock. Pacer Advisors Inc. increased its position in Catalyst Pharmaceuticals by 130,918.8% in the 2nd quarter. Pacer Advisors Inc. now owns 2,967,575 shares of the biopharmaceutical company’s stock valued at $45,968,000 after acquiring an additional 2,965,310 shares during the period. Vanguard Group Inc. increased its stake in shares of Catalyst Pharmaceuticals by 12.1% during the first quarter. Vanguard Group Inc. now owns 7,980,661 shares of the biopharmaceutical company’s stock valued at $127,212,000 after acquiring an additional 860,244 shares during the period. Renaissance Technologies LLC raised its holdings in Catalyst Pharmaceuticals by 15.2% during the second quarter. Renaissance Technologies LLC now owns 2,175,727 shares of the biopharmaceutical company’s stock worth $33,702,000 after purchasing an additional 287,300 shares in the last quarter. Jane Street Group LLC raised its holdings in Catalyst Pharmaceuticals by 245.4% during the third quarter. Jane Street Group LLC now owns 401,908 shares of the biopharmaceutical company’s stock worth $7,990,000 after purchasing an additional 285,564 shares in the last quarter. Finally, Integral Health Asset Management LLC acquired a new stake in Catalyst Pharmaceuticals in the second quarter worth approximately $4,260,000. 79.22% of the stock is currently owned by institutional investors.

Catalyst Pharmaceuticals Company Profile

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.